U.S. top court rules for generic drugmaker on patent

WASHINGTON Wed Apr 18, 2012 5:33am IST

Medication capsules are piectured during packaging process in the production plant of Grindeks in Riga November 23, 2010. REUTERS/Ints Kalnins

Medication capsules are piectured during packaging process in the production plant of Grindeks in Riga November 23, 2010.

Credit: Reuters/Ints Kalnins

Related Topics

Stocks

   

WASHINGTON (Reuters) - The U.S. Supreme Court ruled on Tuesday in favor of a generic drugmaker in a case over how companies can fight brand-name rivals in an effort to get their cheaper medicines to market.

The high court unanimously ruled that the generics company, Caraco Pharmaceuticals, could sue a brand-name drugmaker to get it to narrow its patent description with the Food and Drug Administration.

The FDA uses this information to decide whether to approve a generic "copycat" version of a medicine before the patent has expired.

Caraco, a unit of India's Sun Pharmaceutical Industries, argued that the description of the patent for the diabetes drug, Prandin, was too broad and therefore prevented any generic from entering the market. It raised a "counterclaim" to challenge the description.

The U.S. government said generic drugs saved consumers billions of dollars each year, and it opposed a lower court ruling in favor of the brand-name company, Denmark's Novo Nordisk.

The justices agreed, and overturned a U.S. appeals court ruling that Caraco could not file a legal counterclaim to challenge the way Novo had described its patent to the FDA.

Justice Elena Kagan said in the opinion that when the FDA evaluated an application to market a generic drug, it considered whether the proposed drug would infringe a patent held by the manufacturer of the brand-name version.

The FDA requires brand-name manufacturers to submit descriptions of the scope of their patents, known as use codes, and it assumes the information is accurate, she said.

"We hold that a generic manufacturer may employ this provision to force correction of a use code that inaccurately describes the brand's patent as covering a particular method of using the drug in question," Kagan concluded.

The FDA approved Prandin, known generically as repaglinide, for three separate uses to help patients with Type 2 diabetes to control their blood sugar levels.

Novo Nordisk's main patent on the drug already expired, but it has another that covers the use of repaglinide only when it is used in combination with another diabetes drug, metformin. This patent expires in 2018.

That means Caraco could get FDA approval to "carve out" two other uses for the drug without infringing on Novo Nordisk's specific patent.

But Novo Nordisk, the world's biggest insulin producer, submitted a more general description of its remaining Prandin patent to the FDA, effectively covering all three uses.

Novo Nordisk said its description of the patent for Prandin fulfilled FDA requirements and that the "counterclaim" provision was a minor point in the law that was never supposed to fix patent descriptions. But the Supreme Court rejected the company's arguments.

The Supreme Court case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, No. 10-844.

(Reporting By Anna Yukhananov and James Vicini; Editing by Lisa Von Ahn)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

EBOLA OUTBREAK

REUTERS SHOWCASE

Change Of Venue

Change Of Venue

Parks, playgrounds offer fresh air alternatives to gym workouts.  Full Article 

Antibiotics Quest

Antibiotics Quest

Extreme medicine: The search for new antibiotics.  Full Article 

Biotech Drugs

Biotech Drugs

'Plantibodies' drugs advance as big pharma stands aside.  Full Article 

Promising Vaccine

Promising Vaccine

Experimental chikungunya vaccine shows promise in human trial.  Full Article 

No Unanimity

No Unanimity

Even dentists differ on the best tooth-brushing method.  Full Article 

Importance Of Religion

Importance Of Religion

Religiosity associated with less depression in elderly: study.  Full Article 

Changing Demographic

Changing Demographic

From cradle to grave, Japan's Kewpie adapts menu to feed ageing nation.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage